Tuesday - March 31, 2026
GSK: Bepirovirsen Accepted for Regulatory Review in China as a Potential First-In-Class Functional Cure for Chronic Hepatitis B
March 31, 2026
LONDON, England, March 31 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on March 30, 2026:

* * *

Bepirovirsen accepted for regulatory review in China as a potential first-in-class functional cure for chronic hepatitis B

* Submission supported by statistically significant and clinically meaningful functional cure rates in pivotal Phase III B-Well trials

* An estimated 75 million people in China . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products